Vericel (VCEL) Total Non-Current Liabilities (2010 - 2026)

Vericel's (VCEL) quarterly Total Non-Current Liabilities came in at $127.5 million in Q1 2026, little changed year-on-year from $127.3 million in Q1 2025, and down 2.98% quarter-over-quarter from $131.4 million in Q4 2025.

Vericel (VCEL) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends

Vericel has disclosed Total Non-Current Liabilities across 17 years of filings, most recently posting $127.5 million for Q1 2026.

  • Total Non-Current Liabilities for Q1 2026 came in at $127.5 million, changed 0.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $127.5 million (changed 0.21% YoY), and the FY2025 annual result was $131.4 million, down 6.04% from the prior year.
  • Total Non-Current Liabilities came in at $127.5 million for Q1 2026 at Vericel, down from $131.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $139.9 million in Q4 2024 to a low of $67.8 million in Q1 2022.
  • The 5-year median for Total Non-Current Liabilities is $127.2 million (2025), against an average of $113.4 million.
  • Across the five-year window, Total Non-Current Liabilities soared 61.98% in 2023 and retreated 6.04% in 2025, its largest moves.
  • Vericel's Total Non-Current Liabilities stood at $80.7 million in 2022, then jumped by 58.06% to $127.6 million in 2023, then gained by 9.62% to $139.9 million in 2024, then slipped by 6.04% to $131.4 million in 2025, then retreated by 2.98% to $127.5 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $127.5 million (Q1 2026), $131.4 million (Q4 2025), and $129.7 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 42,980.09
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 11.03 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 95.20 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - 644,700.00
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 5.87 Bn
9 Abivax 91.96 Bn 91.96 Bn - 64.76 Mn
10 Vericel 2.04 Bn 1.90 Bn 49.27 Mn 127.52 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 127.52 Mn
Dec 31, 2025 131.43 Mn
Sep 30, 2025 129.74 Mn
Jun 30, 2025 127.14 Mn
Mar 31, 2025 127.25 Mn
Dec 31, 2024 139.88 Mn
Sep 30, 2024 132.69 Mn
Jun 30, 2024 133.66 Mn
Mar 31, 2024 122.61 Mn
Dec 31, 2023 127.61 Mn
Sep 30, 2023 113.68 Mn
Jun 30, 2023 111.76 Mn
Dec 31, 2022 80.73 Mn
Sep 30, 2022 70.18 Mn
Jun 30, 2022 69.98 Mn
Mar 31, 2022 67.78 Mn
Dec 31, 2021 73.20 Mn
Sep 30, 2021 67.32 Mn
Jun 30, 2021 70.79 Mn
Mar 31, 2021 71.20 Mn